ClinicalTrials.gg
RecruitingNCT04280510ENTEROPATHUpdated Oct 27, 2026

Pathogenic Study of Adult Immune Enteropathies

An observational study in Celiac Disease, Autoimmune Enteropathy and Inflammatory Bowel Diseases, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 4 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Celiac Disease with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Celiac Disease · France.

Started
2020
the only one that year
Observational
6 of 13
2 open now
Registered
5th of 13
by date
Lead sponsor
1 of 13
Institut National de la Santé Et de la Recherche Médicale, France

Among the 13 studies in Celiac Disease with a site in France, this one is the only one that started in 2020, is one of 6 observational ones, and was the 5th registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

3 of the 13 studies in Celiac Disease with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Celiac Disease with a site in France, or all of them as a file.
02

Study summary

The study focuses the mechanisms underlying the loss of intestinal homeostasis in celiac disease, refractory celiac disease and other immune diseases such as monogenic enteropathy, inflammatory bowel diseases or drug induced intestinal diseases. Mechanisms of transformation of lymphocytes leading to onset of lymphomatous complications of immune enteropathies will be investigated. Mechanisms of loss of hepatic lymphocytic homeostasis will also be assessed in liver associated diseases.

03

Conditions studied

  • Celiac Disease
  • Autoimmune Enteropathy
  • Inflammatory Bowel Diseases

Keywords

  • Celiac Disease
  • Autoimmune enteropathy
  • Primary immunodeficiency
  • Intestinal lymphoma
  • Liver autoimmune diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients planned to have blood specimens and possible upper and/or lower digestive endoscopy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or over
  • affiliated to social insurance
  • signed

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • under guardianship
  • not able to sign
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Active coeliac patients

    Patients with active coeliac disease

    Genetic: Blood sample collection; gastrointestinal biopsy

  • Treated coeliac patients

    Patients with coeliac disease on gluten free diet

    Genetic: Blood sample collection; gastrointestinal biopsy

  • Sprue type I

    Patients with refractory coeliac disease of type I

    Genetic: Blood sample collection; gastrointestinal biopsy

  • Sprue type II

    Patients with refractory coeliac disease of type II

    Genetic: Blood sample collection; gastrointestinal biopsy

  • Intestinal Lymphoproliferations

    Patients with intestinal lymphoproliferations

    Genetic: Blood sample collection; gastrointestinal biopsy

  • Non coeliac enteropathies

    Patients with non coeliac immune-mediated enteropathy

    Genetic: Blood sample collection; gastrointestinal biopsy

  • Patients without neoplastic or inflammatory intestinal disease

    Patients without neoplastic or inflammatory intestinal disease

    Genetic: Blood sample collection; gastrointestinal biopsy

Interventions

  • GeneticBlood sample collection; gastrointestinal biopsy

    Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...

06

What researchers measure

Primary outcomes

  1. Intestinal Lymphocytes count

    Lymphocytes isolation

    Time frame: Baseline

  2. DNA sequencing

    Targeted Next Generation sequencing

    Time frame: Baseline

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Feb 2030, 120 months after the start.

Of 48 observational studies under Celiac Disease, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 83. This study's planned 120 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2020
First posted
Feb 21, 2020
StartActual
Feb 27, 2020
Primary completionEst.
Feb 27, 2030
CompletionEst.
Feb 27, 2033
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04280510
Collaborators
Imagine Institute
Responsible party
Sponsor
First posted
Feb 21, 2020
Start date
Feb 27, 2020
Primary completion
Feb 27, 2030 (estimated)
Completion
Feb 27, 2033 (estimated)
Last update
Oct 27, 2026

Study contacts

Georgia MALAMUT, MD, PhD
Contact
georgia.malamut@aphp.fr
33 1 58 41 41 76
Anaïs LEVESCOT, MD, PhD
Contact
anais.levescot@inserm.fr
33 1 42 75 42 77
Georgia MALAMUT, MD, PhD
principal investigator · APHP, Université de Paris (Université Paris Descartes)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion